Finn Kemper from Hauck & Aufhauser retains his Neutral opinion on the stock. The target price has been revised upwards and is now set at EUR 221, compared with EUR 200 previously.
In a research note, Hauck & Aufhauser analyst Finn Kemper has maintained his recommendation on the stock with a Buy rating. The target price remains unchanged at EUR 58.
Initially Neutral on the company, Hauck & Aufhauser s analyst Finn Kemper maintained his recommendation. The target price is lowered from EUR 221 to EUR 200.
Hauck Aufhäuser Investment Banking has upgraded Siemens Healthineers to Buy with a price target of 58 euros. The medical technology group is a leader in a global oligopoly with an estimated market.